Targeting the PI3K signaling pathway in cancer therapy

PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations

(2015) Katsuhiko Nosho et al.   NEOPLASIA

Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799

(2011) Jun Ohwada et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer

(2011) Myles C. Hodgson et al.   CANCER RESEARCH

Current and future directions in mammalian target of rapamycin inhibitors development

(2011) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells

(2011) Tiera A. Liby et al.   INTERNATIONAL JOURNAL OF CANCER

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer

(2011) L. F. Hernandez-Aya et al.   ONCOLOGIST

E17K substitution in AKT1 in prostate cancer

(2010) J L Boormans et al.   BRITISH JOURNAL OF CANCER

Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations

(2010) Shingo Dan et al.   CANCER RESEARCH

PIK3CA Mutations in In situ and Invasive Breast Carcinomas

(2010) A. Miron et al.   CANCER RESEARCH

PTEN mutation spectrum in breast cancers and breast hyperplasia

(2010) JuLun Yang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type

(2010) Stefano Barbi et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth

(2009) Jorge Blando et al.   AMERICAN JOURNAL OF PATHOLOGY

Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling

(2009) Christina Gewinner et al.   CANCER CELL

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

(2009) K. Kalinsky et al.   CLINICAL CANCER RESEARCH

AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma

(2009) Yoram Cohen et al.   GYNECOLOGIC ONCOLOGY

Molecular alterations inAKT1,AKT2andAKT3detected in breast and prostatic cancer by FISH

(2009) Tove Kirkegaard et al.   HISTOPATHOLOGY

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K

(2009) J M Askham et al.   ONCOGENE

Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest

(2008) Shingo Dan et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

(2008) M S Kim et al.   BRITISH JOURNAL OF CANCER

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

(2008) H. Yamamoto et al.   CANCER RESEARCH

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

(2008) J LOPICCOLO et al.   DRUG RESISTANCE UPDATES

mTOR inhibitors in the treatment of cancer

(2008) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE